NTLA vs VRTX

For growth investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger pick with 9.

6% revenue growth year-over-year, versus -100. 0% for Intellia Therapeutics, Inc. (NTLA). Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 27. 7x trailing P/E (22. 1x forward), making it the more compelling value choice. Analysts rate Intellia Therapeutics, Inc. (NTLA) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +98.

4%, compared to -81. 3% for Intellia Therapeutics, Inc. (NTLA). Over 10 years, the gap is even starker: VRTX returned +405. 2% versus NTLA's -39. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.

82β versus Intellia Therapeutics, Inc. 's 2. 37β — meaning NTLA is approximately 189% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Intellia Therapeutics, Inc. (NTLA) carries a lower debt/equity ratio of 14% versus 21% for Vertex Pharmaceuticals Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vertex Pharmaceuticals Incorporated (VRTX) is pulling ahead at 9.

6% versus -100. 0% for Intellia Therapeutics, Inc. (NTLA). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to 27. 4% for Intellia Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus 0. 0% for Intellia Therapeutics, Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus 0. 0% for NTLA. At the gross margin level — before operating expenses — VRTX leads at 85. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NTLA: 56.

9% to $20. 88.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

82), +405. 2% 10Y return). Intellia Therapeutics, Inc. (NTLA) carries a higher beta of 2. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VRTX: +405. 2%, NTLA: -39. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.